Abstract
Objective
To observe the therapeutic effect and safety of Qianggan Capsule (强肝胶囊, QGC) in treating non-alcoholic fatty liver disease (NAFLD), using polyene phosphatidylcholine capsule (PPC) as a reference.
Methods
Eighty-eight patients with NAFLD were randomly assigned to two groups, 45 in the treatment group treated with QGC and 43 in the control group treated with PPC. The course of treatment lasted for 6 months. Changes in liver function, blood lipids, and iconographic indexes before and after treatment were observed, and clinical efficacy was evaluated.
Results
In the treatment group, alanine aminotransferase (ALT) was lowered significantly from 56.02±32.59 IU/L before treatment to 38.27±22.68 IU/L after treatment, and CT liver/spleen ratio significantly increased from 0.69±0.18 to 0.91±0.25, showing statistical significance (P<0.05); in contrast, the corresponding changes of the two indexes in the control group were 56.56±26.33 IU/L to 49.67±26.22 IU/L, and 0.66±0.20 to 0.75±0.24, respectively, the pre-post treatment difference showing insignificant difference (P>0.05). No severe adverse reactions occurred during the whole treatment course.
Conclusion
QGC is an effective and safe remedy for the treatment of NAFLD.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Neuschwander-Tetri BA, Brunt EM, Wehmeier KR, Oliver D, Bacon BR. Improved nonalcoholic steatohepatitis after 48 weeks of treatment with the PPAR-γ ligand rosiglitazone. Hepatology 2003;38:1008–1017.
Fatty Liver and Alcoholic Liver Disease Study Group of Chinese Society of Hepatology, Chinese Medical Association. Guidelines for diagnosis and treatment of nonalcoholic fatty liver diseases. Chin J Hepatol (Chin) 2006;14:161–163.
Li F, Fan JG, Cai XB. Non-alcoholic fatty liver disease promotes the development of metabolic abnormalities. Chin Hepatol 2006;11:7–11.
Zhang L, Jia JD. Pathogenesis of non-alcoholic fatty liver and pharmacotherapy. Clin Med J (Chin) 2005;3(4):21–23.
Zeng MD. Stress on research of nonalcoholic fatty liver disease. Chin J Hepatol (Chin) 2003;11(2):69–70.
Alba LM, Lindor K. Review article: non-alcoholic fatty liver disease. Aliment Pharmacol Ther 2003;17:977–986.
Cheng CX, Peng JH, Zhao YD, Yin JP. Ultrasound and CT quantitative diagnosis of diffuse fatty infiltration of the liver. Chin Imaging J Integr Tradit West Med (Chin) 2006;4:440–441.
Zou Q, Wang B, Li LX, Lu SJ, Sun XH. Single-energy CT quantitative diagnosis of fatty liver: an experimental study. J Clin Radiol (Chin) 2002;21:150–154.
Zeng BH, Huang DZ, Fan LY. Clinical observation of the treatment on fatty liver by Essentiale. Pract Clin J Integr Tradit Chin West Med (Chin) 2006;6(10):25–26.
Ding XC, Ma LN, Zhang X. Influence of Qianggan Capsule on indexes of hepatic fibrosis in patients of chronic liver disease. Chin J Integr Tradit West Med Dig (Chin) 2003;11:351.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Li, L., Zhang, Xj., Lan, Y. et al. Treatment of non-alcoholic fatty liver disease by Qianggan Capsule (强肝胶囊). Chin. J. Integr. Med. 16, 23–27 (2010). https://doi.org/10.1007/s11655-010-0023-1
Received:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11655-010-0023-1